GM1 added to clot removal for stroke caused by a large blocked artery

Trial details

Who runs it

Xuanwu Hospital, Beijing

Trial code

NCT07519044

Record updated

24 June 2026

Original description

Stroke is a leading cause of global mortality and morbidity, with acute ischemic stroke (AIS) accounting for approximately 65.3% of cases and resulting in roughly 3.4 million new cases annually in China. While endovascular thrombectomy (EVT) is the recommended first-line therapy for large vessel occlusion (LVO), achieving 80-90% recanalization, fewer than 50% of patients reach functional independence (mRS 0-2) due to "futile recanalization" caused by mechanisms like no-reflow and reperfusion injury. Monosialotetrahexosylganglioside (GM1) is a unique glycosphingolipid that crosses the blood-brain barrier to provide neuroprotection by suppressing oxidative stress, excitotoxicity, and apoptosis while promoting neurogenesis. Although Phase III trials like the FOCUS study confirmed GM1's safety and efficacy in AIS populations, its benefit specifically for patients undergoing mechanical thrombectomy remains unkown. Therefore, the IAT-GIANT study is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of adjunctive GM1 in improving 90-day functional outcomes for AIS-LVO patients treated with EVT.Read full original descriptionShow less

Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study-IAT-GIANT (Ganglioside GM1 to Improve Outcomes in Anterior CirculatioN Thrombectomy)

Stroke is a leading cause of global mortality and morbidity, with acute ischemic stroke (AIS) accounting for approximately 65.3% of cases and resulting in roughly 3.4 million new cases annually in China. While endovascular thrombectomy (EVT) is the recommended first-line therapy for large vessel occlusion (LVO), achieving 80-90% recanalization, fewer than 50% of patients reach functional independence (mRS 0-2) due to "futile recanalization" caused by mechanisms like no-reflow and reperfusion injury. Monosialotetrahexosylganglioside (GM1) is a unique glycosphingolipid that crosses the blood-brain barrier to provide neuroprotection by suppressing oxidative stress, excitotoxicity, and apoptosis while promoting neurogenesis. Although Phase III trials like the FOCUS study confirmed GM1's safety and efficacy in AIS populations, its benefit specifically for patients undergoing mechanical thrombectomy remains unkown. Therefore, the IAT-GIANT study is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of adjunctive GM1 in improving 90-day functional outcomes for AIS-LVO patients treated with EVT.

Inclusion: 1.Age ≥18 years and ≤80 years; 2.Symptoms and signs consistent with anterior circulation ischemia; 3.Computed tomography angiography (CTA) /magnetic resonance angiography (MRA) /digital subtraction angiography (DSA) confirmed occlusion of intracranial segment of internal carotid artery (ICA) or M1/M2 segments of the middle cerebral artery (MCA M1/M2); 4.Acute ischemic stroke (AIS) selected for emergency endovascular treatment; 5.Premorbid mRS ≤1; 6.Time from symptom onset to randomization was within 24 hours, including patients with wake-up stroke or unwitnessed stroke; The time of symptom onset was defined as the Last Known Well (LKW); 7.National Institutes of Health Stroke Score (NIHSS) ≥6 at admission; 8.ASPECTS ≥3; 9.Informed consent obtained from the patient or his/her legal representative.

Exclusion: 2.Baseline NIHSS is not obtained by a neurologist or emergency physician prior to sedation or intubation; 7.Systolic pressure >185 mmHg or diastolic pressure >110 mmHg, and cannot be controlled by antihypertensive drugs; 3.Seizures at stroke onset which would preclude obtaining a baseline NIHSS; 5.Allergy to GM1 or excipients; 6.Severe contrast allergy or absolute contraindication to iodinated contrast; 15.Evidence indicates intracranial tumors (excluding small meningiomas), acute intracranial hemorrhage, tumors, or arteriovenous malformations (AVMs); 17. The patient has neurological disease or mental disorder before onset, which affects the assessment of the condition; 19.Hereditary glycolipid metabolic disorders (ganglioside storage diseases, such as familial amaurotic idiocy, retinal degenerative diseases); 20.Autoimmune diseases, spine injuries, demyelinating diseases (e.g., Guillain-Barre syndrome); 8.Blood glucose <50 mg/dl (2.8 mmol/L) or >400 mg/dl (22.2 mmol/L); 9.Platelet <50*10\^9/L; 10.Known genetic or acquired bleeding diathesis, deficiency of anticoagulant factors, or oral anticoagulant drugs and INR > 1.7, or treated with direct oral anticoagulant agents in the prior 48 hours; 11.Known Severe renal Failure as defined by a serum creatinine > 3.0 mg/dl (or 265.2 μmol/l) or glomerular filtration rate (GFR) <30, or patient requires hemodialysis or peritoneal dialysis; 1.Simultaneous acute occlusion of large vessels in both the anterior and posterior circulation or bilateral cerebral hemispheres; 4.Bilateral dilated pupils; 12.Patients that cannot complete 90-day follow-up (e.g. no fixed residence, overseas patients, etc.); 13.Presumed vasculitis or septic embolization; 14.Suspicion of aortic dissection; 16. Significant mass effect causing midline shift; 18.Females who are pregnant or in lactation; 21.Participating in other clinical trials that could confound the evaluation of the study; 22.Other circumstances that the investigator considers inappropriate for participation or may pose a significant risk to patients.

ClinicalTrials.gov NCT07519044